Study Casts Doubt Over Widely Prescribed Beta Blocker Atenolol

Main Category: Cardiovascular / Cardiology
Article Date: 05 Nov 2004 - 15:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Results of a study in this week's issue of THE LANCET (p 1684) suggest that atenolol - one of the most widely prescribed beta-blockers for reducing blood pressure-may not be effective in reducing heart attacks or death from cardiovascular causes.

Atenolol is one of the most commonly used beta-blockers clinically, and has often been used as a reference drug in randomised controlled trials of high blood pressure. Concerns that atenolol may not be the best reference drug for comparison with other antihypertensive drugs led Bo Carlberg (Umea University Hospital, Sweden) and colleagues to systematically review the effect of atenolol on cardiovascular illness and death among patients with high blood pressure.

The investigators identified four studies that compared atenolol with placebo or no treatment, and five studies that compared atenolol with other antihypertensive drugs.

Atenolol was no different to placebo in terms of death from all causes, cardiovascular causes, or incidence of heart attack; a trend in reduced stroke incidence was the only favourable outcome. Atenolol slightly increased all-cause mortality compared with other antihypertensive drugs, in addition to showing a trend to increased cardiovascular death and increased stroke incidence.

Co-author Lars H Lindholm comments: "We have some doubts about the suitability of atenolol as a first-line antihypertensive drug and as a reference drug in outcome trials of hypertension."

Contact: Professor Lars Hjalmar Lindholm, Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden; T) +46 90 785 3526; mobile +46 70 585 35 26; LarsH.Lindholm@fammed.umu.se

Dr. Bo Carlberg, Umea University Hospital T) +46 90 785 1443; mobile +46 70 577 58 83; Bo.Carlberg@medicin.umu.se

THE LANCET
T) +44 (0) 20 7424 4910
F) +44 (0) 20 7424 4911
E-mail:editorial@lancet.com
Editor - Richard Horton
Deputy Editor - Astrid James
Executive Editors
Sabine Kleinert
David McNamee
Pia Pini
Charles Young
Managing Editor - Stephanie Clark
North American Editor
Michael McCarthy (Seattle)
T) +1 206 706 7461
North American Senior Editor
Faith McLellan (New York)
T) +1 212 633 3801
European Senior Editor
Patricia Schlagenhauf (Zurich)
T) +41 1 3627604
http://www.thelancet.com